Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Purchases 3,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour purchased 3,000 shares of Neonc Technologies stock in a transaction that occurred on Monday, August 17th. The stock was bought at an average cost of $4.37 per share, with a total value of $13,110.00. Following the completion of the transaction, the chief executive officer owned 3,087,000 shares of the company’s stock, valued at $13,490,190. The trade was a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Neonc Technologies Stock Performance

Shares of NTHI stock traded up $0.69 during mid-day trading on Monday, hitting $4.91. 378,880 shares of the stock were exchanged, compared to its average volume of 92,168. The stock’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $6.08. Neonc Technologies Holdings, Inc. has a 12-month low of $3.01 and a 12-month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last announced its earnings results on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Analyst Ratings Changes

NTHI has been the topic of a number of recent research reports. Alliance Global Partners began coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Maxim Group began coverage on Neonc Technologies in a report on Monday, May 18th. They set a “buy” rating and a $20.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, May 26th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Neonc Technologies has an average rating of “Hold” and an average price target of $16.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. HighPoint Advisor Group LLC lifted its position in Neonc Technologies by 20.5% in the fourth quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock valued at $9,466,000 after purchasing an additional 194,408 shares during the period. Westmount Partners LLC increased its position in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in Neonc Technologies during the 4th quarter worth approximately $126,000. Barclays PLC raised its stake in shares of Neonc Technologies by 5,314.8% during the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after buying an additional 8,982 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Neonc Technologies by 9.9% during the 4th quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after buying an additional 3,900 shares in the last quarter.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.